中信建投证券股份有限公司 关于卧龙新能源集团股份有限公司 本次交易前 12 个月内购买、出售资产的核查意见 卧龙新能源集团股份有限公司（以下简称"公司"、"上市公司"）拟向浙 江卧龙舜禹投资有限公司出售其持有的卧龙矿业（上海）有限公司 90%股权（以 下简称"标的资产"）（以下简称"本次交易"、"本次重组"、"本次重大资 产重组"）。 经核查，独立财务顾问认为：除上述交易外，上市公司本次交易前 12 个月 内未发生《上市公司重大资产重组管理办法》规定的其他重大资产购买、出售事 项，不存在购买、出售与本次重大资产重组标的资产为同一或相关资产的情形。 （以下无正文） 中信建投证券股份有限公司（以下简称"独立财务顾问"）作为本次重大资产 重组的独立财务顾问，对上市公司本次交易前 12 个月内购买、出售资产的情况 进行核查。如无特别说明，本核查意见中的简称和释义与《卧龙新能源集团股份 有限公司重大资产出售暨关联交易报告书（草案）》中的简称和释义具有相同含 义。 根据《上市公司重大资产重组管理办法》第十四条第四款的规定：上市公司 在十二个月内连续对同一或者相关资产进行购买、出售的，以其累计数分别计算 相应数额。已按照本 ...

Group 1 - The core viewpoint of the article is that the transaction involving the sale of 100% equity of Wolong Mining (Shanghai) Co., Ltd. by Wolong New Energy Group Co., Ltd. complies with relevant regulations regarding the hiring of third parties in investment banking activities [1][2] - The independent financial advisor confirmed that there were no direct or indirect paid engagements of third parties in the financial advisory services for this merger and acquisition [1][2] - The company did not engage any other third-party institutions or individuals beyond the legally required securities service institutions such as independent financial advisors, law firms, accounting firms, and asset appraisal agencies for this transaction [2]

Group 1 - The company, Wolong New Energy Group Co., Ltd., plans to sell 90% equity of Wolong Mining (Shanghai) Co., Ltd. to Zhejiang Wolong Shunyu Investment Co., Ltd. as part of a major asset restructuring [1] - The independent financial advisor, CITIC Construction Investment Securities Co., Ltd., conducted a review of the stock price fluctuations of the company prior to the announcement of the transaction [1] - The stock price on the last trading day before the announcement (April 11, 2025) was 6.71 CNY per share, compared to 5.86 CNY per share on March 13, 2025, indicating a cumulative increase of 14.51% over the 20 trading days prior to the announcement [2] Group 2 - The Shanghai Composite Index decreased by 3.59% during the same period, while the China Securities Regulatory Commission's real estate index fell by 2.56% [2] - After excluding the impact of the overall market, the company's stock price increased by 18.09% over the 20 trading days prior to the announcement [2] - The stock price increase of 17.06% was observed after excluding the influence of the industry sector, indicating that there were no abnormal fluctuations in the stock price [2]

Group 1 - The core viewpoint of the article is that the transaction involving the sale of 90% equity of Shanghai Mining by Wolong New Energy Group does not constitute a restructuring listing as per the regulations outlined in the Major Asset Restructuring Management Measures for Listed Companies [1][2] - The transaction is classified as a major asset sale, which does not involve the issuance of shares and will not change the equity structure of the listed company [1] - The controlling shareholder remains Zhejiang Wolong Real Estate Investment Co., Ltd., and the actual controller is still Mr. Chen Jiancheng, indicating that there is no change in control of the listed company [1][2] Group 2 - The independent financial advisor, CITIC Construction Investment Securities Co., Ltd., confirms that the transaction will not lead to a change in control of the listed company [2] - The audited financial data for the fiscal year 2024 shows that the revenue from Shanghai Mining accounts for over 50% of the total revenue of the listed company, qualifying the transaction as a major asset restructuring [1]

Group 1 - The company plans to sell 90% equity of Wolong Mining (Shanghai) Co., Ltd. to Zhejiang Wolong Shunyu Investment Co., Ltd. as part of a major asset restructuring [1] - The independent financial advisor conducted a review of the insider information registrant system established by the company and confirmed its compliance with relevant laws and regulations [2] - The company implemented necessary confidentiality measures during the transaction planning period, limiting the knowledge of sensitive information to a defined group of individuals [1][2] Group 2 - The independent financial advisor concluded that the company adhered to the insider information registrant system and took adequate confidentiality measures during the transaction [2]

Group 1 - The core event involves a block trade of 320,000 shares of Industrial and Commercial Bank of China (ICBC) on May 22, 2025, with a transaction value of 2.0576 million yuan at a price of 6.43 yuan, reflecting a discount of 9.69% compared to the closing price of 7.12 yuan on that day [1] - The buyer of the block trade was First Capital Securities Co., Ltd., while the seller was CITIC Construction Investment Securities Co., Ltd. This transaction accounted for 0.10% of ICBC's total trading volume of 20.96 billion yuan on that day [1] - On the same day, ICBC's stock opened at 7.15 yuan, reached a high of 7.16 yuan, and a low of 7.10 yuan, closing down 0.28% at 7.12 yuan, with a total trading volume of 2.9408 million hands and a turnover rate of 0.11% [1] Group 2 - ICBC announced the approval for the listing of various notes on the Hong Kong Stock Exchange, including a floating rate note of 1 billion USD issued by its Hong Kong branch, a 300 million USD note with a 4.125% interest rate issued by its Singapore branch, and a 3 billion yuan note with a 2.00% interest rate issued by its Dubai branch [1] - The bank stated that its deposit rates are generally in line with major comparable peers, and the enhanced linkage between deposit and loan rates helps balance the service to the real economy and stabilize the bank's interest margin [1] - In the past three months, ICBC has experienced multiple block trades, including a notable transaction on May 15, where 1.8851 million shares were traded at 6.58 yuan, reflecting a discount of 9.49% [2]

Core Viewpoint - The company, Beijing Tianzhihang Medical Technology Co., Ltd., has undergone multiple rounds of public offerings and has established a robust continuous supervision mechanism to ensure compliance and operational efficiency in the orthopedic surgical robot industry [1][2][3]. Group 1: Fundraising and Financial Performance - The company raised a total of RMB 504.48 million by issuing 41.9 million shares at a price of RMB 12.04 per share in its initial public offering [1]. - In a subsequent offering, the company issued 29.55 million shares at RMB 12.53 per share, raising RMB 370.20 million, with a net amount of RMB 359.76 million after deducting issuance costs [2]. - The company's revenue for 2024 was RMB 178.84 million, representing a year-on-year decrease of 14.85% compared to RMB 210.04 million in 2023 [12]. Group 2: Continuous Supervision and Compliance - The company has established a continuous supervision work plan in accordance with the regulations set by the China Securities Regulatory Commission, ensuring effective execution of supervisory duties [3][4]. - The company has signed a continuous supervision agreement with its sponsor, which outlines the rights and obligations of both parties during the supervision period [3]. - The sponsor has conducted regular communication, site inspections, and due diligence to monitor the company's compliance with laws and regulations [4][5]. Group 3: Operational Risks and Challenges - The company has not yet achieved profitability, with a net loss of RMB 121.13 million in 2024, although the loss has narrowed compared to RMB 156.39 million in the previous year [12][7]. - The orthopedic surgical robot industry is characterized by high technical barriers and significant R&D investment, which poses risks related to product development and market competition [8][9]. - The company faces potential risks from supply chain disruptions and regulatory changes that could impact its production and sales capabilities [10][11]. Group 4: Competitive Advantages and Innovations - The company has established a strong competitive edge through its "production, learning, research, and medical" collaborative innovation mechanism, partnering with leading universities and hospitals [13][15]. - The company has accumulated a total of 596 patent applications, with 401 patents granted, establishing a technological barrier in the orthopedic surgical robot field [15][16]. - The company has successfully developed multiple iterations of its orthopedic surgical robots, gaining recognition for their clinical advantages such as precision and minimally invasive procedures [13][14].

Core Viewpoint - The company, Meixin Sheng Technology (Beijing) Co., Ltd., successfully issued 20,010,000 shares at a price of 75.00 RMB per share, raising a total of 150,075.00 million RMB, with a net amount of 137,648.31 million RMB after deducting issuance costs [1]. Continuous Supervision Work - The sponsoring institution has established and effectively executed a continuous supervision work plan, including signing rights and obligations with the company and conducting regular communications, visits, and inspections [2][3]. - During the supervision period, the company did not have any violations or breaches of commitments [3][4]. Financial Performance - For the fiscal year 2024, the company reported a revenue of 404.17 million RMB, a decrease of 14.43% compared to the previous year [13]. - The net profit attributable to shareholders was -66.57 million RMB, a significant decline of 320.76% year-on-year [13]. - The company’s cash flow from operating activities was -77.08 million RMB, indicating a worsening cash flow situation [13]. Research and Development - The company increased its R&D expenditure by 59.73% to 164.11 million RMB, representing 40.60% of its revenue [22]. - The company has accumulated a total of 286 intellectual property applications, with 178 granted, including 3 international invention patents [20][23]. Market and Industry Risks - The company faces risks related to significant performance declines or losses due to macroeconomic conditions and intensified market competition [7]. - The semiconductor industry is characterized by rapid technological changes, and the company must continuously innovate to maintain its competitive edge [8]. Core Competitiveness - The company has developed a robust technological foundation through systematic innovation and high-integration technology, maintaining a leading position in several niche markets [15][16]. - The company has established strategic partnerships with leading clients, enhancing its market competitiveness and ensuring stable demand for its products [21]. Use of Raised Funds - The total amount raised was 150,075.00 million RMB, with 82,036.57 million RMB already invested in projects, and the remaining balance is being managed in compliance with regulations [25].

承董事會命 中信建投証券股份有限公司 董事長 劉 成 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6066） 海外監管公告 本 公 告 乃 中 信 建 投 証 券 股 份 有 限 公 司（「本公司」）根 據 香 港 聯 合 交 易 所 有 限公司證券上市規則第13.10B條 而 作 出。 茲 載 列 本 公 司 於 上 海 證 券 交 易 所 網 站 刊 發 之《中 信 建 投 証 券 股 份 有 限 公 司2025年 面 向 專 業 投 資 者 公 開 發 行 短 期 公 司 債 券（第 一 期）發 行 結 果 公 告》，僅 供 參 閱。 中國北京 2025年5月22日 於 本 公 告 日 期，本 公 司 執 行 董 事 為 劉 成 先 生 及 金 劍 華 先 生；本 公 司 非 執 行 董 事 為 李 岷 先 生、閆 小 ...

根据合并数据显示，多头前三席位为中信期货，总持仓38316、乾坤期货，总持仓25019、国泰君安，总持仓23071；空头前三席位 为东证期货，总持仓32995、国泰君安，总持仓29487、中信期货，总持仓23676； 主力合约前20席位中，多头增仓前三名分别是：一德期货、持仓19422、增仓2913，中泰期货、持仓5310、增仓273，中信建投、 持仓6395、增仓253；多头减仓前三名分别是：中信期货、持仓13547、减仓-3755，华泰期货、持仓2286、减仓-935，国泰君安、 持仓13868、减仓-851； 新浪期货 根据交易所数据，截至5月22日收盘主力合约豆一2507,涨跌-0.29%,成交量12.30万手，持仓数据显示前20席位呈现净空， 差额头寸为3117手。 豆一期货全合约总计成交19.53万手，比上一日减少8.81万手。全合约前20席位多头持仓23.55万手，比上一日减少1611手。全合约 前20席位空头持仓25.10万手，比上一日增加284手。 | | | | | 2025年5月22日豆一全合约持仓数据一览 | | | | | | | --- | --- | --- | --- | -- ...